Orchard Therapeutics Plc logo

Orchard Therapeutics Plc Share Price (NASDAQ: ORTX)

▲

-16.7

(-100%)

Last updated on

Bell Icon

This instrument is not available for trading on the INDmoney app on 23 Jan 2024

Check the interactive Orchard Therapeutics Plc Stock chart to analyse performance

Orchard Therapeutics Plc Key Stats

Check Orchard Therapeutics Plc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$16.7
Open
$16.65
Market Capitalization
$380.1M
Today's Volume
$372.3K
Revenue TTM
$21.8M
EBITDA
$-99.3M
Earnings Per Share (EPS)
$-4.1
Dividend Yield
0.0%
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-71.51%

Global Institutional Holdings in Orchard Therapeutics Plc

  • Name

    Holdings %

  • CHI Advisors LLC

    54.11%

  • Deep Track Capital, LP

    8.97%

  • Federated Hermes Inc

    3.82%

  • Deerfield Management Co

    1.39%

  • Junked Platinum Investment Management Ltd

    1.09%

  • Mariner Wealth Advisors, LLC

    0.84%

Analyst Recommendation on Orchard Therapeutics Plc Stock

Rating
Trend

Hold

    0%Buy

    62%Hold

    37%Sell

Based on 8 Wall street analysts offering stock ratings for Orchard Therapeutics Plc(by analysts ranked 0 to 5 stars)

About Orchard Therapeutics Plc

Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Organization
Orchard Therapeutics Plc
Employees
166
CEO
Dr. Bobby Gaspar M.D., Ph.D.
Industry
Health Technology

Important FAQs about investing in ORTX Stock from India :

What is Orchard Therapeutics Plc share price today?

Orchard Therapeutics Plc share price today is as on at the close of the market. Orchard Therapeutics Plc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Orchard Therapeutics Plc share?

Orchard Therapeutics Plc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Orchard Therapeutics Plc stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in Orchard Therapeutics Plc Stock (ORTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Orchard Therapeutics Plc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Orchard Therapeutics Plc Shares .

What is the minimum amount required to buy Orchard Therapeutics Plc Stock (ORTX) from India?

Indian investors can start investing in Orchard Therapeutics Plc (ORTX) shares with as little as ₹93.46 or $1 (as of March 21, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹934.60 in Orchard Therapeutics Plc stock (as per the Rupee-Dollar exchange rate as on March 21, 2026). Learn more about fractional shares .

What are the returns that Orchard Therapeutics Plc has given to Indian investors in the last 5 years?

Orchard Therapeutics Plc stock has given 0.0% share price returns and 29.12% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?